Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCS -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (16)	1/21/2001 6:47:32 PM
From: Mark Bong	Respond to of 78

AMGN and PRCS seem to be taking the line that Abarelix has a better therapeutic advantage over others because it inhibits Follicle Stimulating Hormones, which also cause cancer growth. They will start trials on this soon. We shall see. Abarelix still looks like the best treatment, but how much better it is still remains to be seen. Take care. Mark <It is the only prostate treatment that acts as an inhibitor on follicle stimulating hormones, which apparently also cause cancer to progress.> This is what PRCS and AMGN said at the JPMorgan conference.